CIK 0001658551 · Non-accelerated filer<br>Smaller reporting company
Amylyx Pharmaceuticals, Inc.
Sign in to watch- Ticker
- AMLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464600503
- Phone
- 617-682-0917
- Business address
- 55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE, MA, 02142
- 8-K Event Results of operations
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G Stake Amended Statement of Ownership
- 4 Gift Director gave 9,100 shares (gift)
- 4 Gift Director gave 94,350 shares (gift)
- 4 Open-market sale Co-Chief Executive Officer sold 5,841 shares at $16.33 ($95,372)
- 4 Open-market sale Chief Financial Officer sold 2,716 shares at $16.33 ($44,347)
- 4 Open-market sale Co-Chief Executive Officer sold 5,841 shares at $16.33 ($95,372)
- 4 Open-market sale Chief Medical Officer sold 2,812 shares at $16.33 ($45,915)
- 4 Option exercise Chief Commercial Officer acquired 25,000 shares (option exercise)
- UPLOAD Other SEC-generated Letter
- 4 Open-market buy Director bought 4,000 shares at $14.97 ($59,880)
- CORRESP Other Correspondence Between Filers and SEC Staff
- SC 13G Stake Amended Statement of Ownership
- 8-K Event Regulation FD disclosure
- UPLOAD Other SEC-generated Letter
- 4 Grant or award Chief Medical Officer acquired 58,333 shares (grant or award)
Page 13 of 23 · 446 filings